New York, Feb 7, 2026, 09:35 EST — The market remains shut.
- Roivant surged 22.4% to finish at $25.82 on Friday after putting out its Phase 2 results and reporting quarterly numbers.
- The company said its once-daily brepocitinib beat placebo in a study for a rare skin disease. Phase 3 is lined up for 2026.
- Investors are eyeing what the FDA does next with a dermatomyositis submission. Fresh analyst commentary is also on tap after the weekend.
Roivant Sciences Ltd shares jumped Friday after the company reported promising mid-stage results for brepocitinib, its immune-modulating drug targeting a rare skin disorder. The update came with the release of the firm’s latest quarterly earnings.
Nasdaq shares jumped 22.4%, closing at $25.82. Next up: traders weighing whether this rally holds when U.S. markets return Monday, Feb. 9.
Roivant wants to get its late-stage pipeline over the finish line and into approvals, a crucial play with investors eager for biotech names that nail efficacy in controlled trials. The company has flagged a handful of milestones set for 2026; investors are already watching that timeline closely.
Fresh numbers focus on cutaneous sarcoidosis—a chronic inflammatory disease causing skin lesions. Roivant pointed out there are no approved therapies yet, so the trial design and regulatory feedback set to come are particularly important.
Roivant said its BEACON trial saw disease activity scores drop 22.3 points at Week 16 for patients on the 45-mg dose of brepocitinib—out of 31 total in the study. Placebo barely budged: a 0.7-point decline. For the 45-mg group, 62% achieved “functional remission.” Placebo patients? Not a single one. No serious adverse events were reported during the treatment window. 1
Misha Rosenbach, the study’s lead investigator at the University of Pennsylvania, put it bluntly: “The topline of the message I would want to convey is: You could not see better results in the drug,” Rosenbach told STAT. 2
Priovant expects to start a Phase 3 trial in cutaneous sarcoidosis in 2026 after talks with the U.S. Food and Drug Administration, according to the company. Roivant has submitted a New Drug Application to the FDA for brepocitinib focused on dermatomyositis, and said topline Phase 3 data for non-infectious uveitis remain slated for the second half of 2026.
Roivant turned in $2.0 million in revenue for the quarter ended Dec. 31, 2025. Net loss from continuing operations came to $313.7 million, or $0.38 a share. By Dec. 31, the company reported a consolidated cash balance—spanning cash, equivalents, restricted cash and marketable securities—of about $4.5 billion. 3
Leerink Partners’ David Risinger called the results “exceptional,” Investors.com reported, highlighting the data as support for blockbuster potential across multiple indications. 4
The cutaneous sarcoidosis study wasn’t large, so there’s a real chance bigger trials could wash out those initial signals—or turn up safety issues that a 16-week snapshot would miss. Regulators could take issue with anything from endpoints to dosing choices, or even question how “remission” is defined in any pivotal program.
Next week, investors are eyeing further analyst reactions and searching for details on the Phase 3 trial design once talks with the FDA wrap up. Questions remain about when the FDA will finish reviewing the dermatomyositis filing. Roivant has also pointed to a jury trial set for March 2026 in Genevant’s U.S. suit against Moderna as a major date, with multiple clinical readouts expected throughout both halves of 2026.
